Chr. Hansen - Bioscience-basierte Ingredienzen für den Nahrungsmittel-, Gesundheits- und Futtermitte
eröffnet am 19.11.18 12:39:16 von
neuester Beitrag 14.12.23 10:40:23 von
neuester Beitrag 14.12.23 10:40:23 von
Beiträge: 9
ID: 1.292.923
ID: 1.292.923
Aufrufe heute: 0
Gesamt: 1.329
Gesamt: 1.329
Aktive User: 0
ISIN: DK0060227585 · WKN: A1CZWD
75,00
EUR
+0,68 %
+0,51 EUR
Letzter Kurs 30.01.24 Lang & Schwarz
Neuigkeiten
29.01.24 · globenewswire  |
26.01.24 · globenewswire |
20.12.23 · globenewswire |
19.12.23 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 53,50 | +98,15 | |
| 1,3500 | +29,82 | |
| 4,5700 | +24,18 | |
| 1,8300 | +23,65 | |
| 2,7800 | +22,47 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7008 | -15,56 | |
| 0,7603 | -15,56 | |
| 2,8600 | -19,21 | |
| 5,2000 | -27,78 | |
| 9,6800 | -33,29 |
Beitrag zu dieser Diskussion schreiben
Feedback
Sieht doch gut aus , sehr langfristig gesehen.
Sieht doch gut aus , langfristig:
January 14, 2021 01:59 ET | Source: Chr. Hansen Holding A/S
Company Announcement No. 01
Strong organic growth and good commercial traction; integration of acquisitions on track
Q1 2020/21 organic sales growth was 10%, equally split between volume/mix and price, and driven by Health & Nutrition which delivered 15% growth while Food Cultures & Enzymes delivered 8% growth
Underlying EBIT margin b.s.i. (see reconciliation on p. 20) of 28.5%, incl. 1%-point negative currency impact, compared to 29.0% in Q1 2019/20. Reported EBIT margin b.s.i. (incl. all acquisition impacts) was 25.2%
Integration of probiotic acquisitions well on track, but temporary capacity constraints in HMO will phase part of expected FY21 revenues and capex to FY22
Outlook for 2020/21 is unchanged on all key parameters
CEO Mauricio Graber says: “Our first quarter came in quite strong on a relatively easy comparable from Q1 last year, with good performance across our business, especially within Health & Nutrition. We were able to win new business, launch new products in Food Cultures & Enzymes and drive upselling in key markets such as cheese – all despite the difficulties of COVID-19. We have more product launches scheduled for the current financial year, which will help to ensure that we have a healthy commercial pipeline in the years to come.
Chr. Hansen is on track to execute on our 2025 strategy and become a focused bioscience company based on a unique microbial and fermentation technology platform. This is a year of transition, where we need to secure a succesful integration of the acquired businesses. We have started out strong, and we will address any challenges that may arise in those processes head on and with determination. The divestment process of Natural Colors is also on track and the business delivered as expected.
Our outlook for 2020/21 remains cautious, and despite COVID-19 we are able to maintain our outlook on all key parameters. This means that we will still outgrow the underlying markets as we strive to deliver industry-leading growth rates.”
Outlook for 2020/21
Organic revenue growth: 5-8%
EBIT margin before special items: 27-28%
Free cash flow before special items, acquisitions and divestments: EUR 120-160 million
The guidance for EBIT margin before special items and for free cash flow before acquisitions and special items assumes constant currencies from the time of this announcement and for the remainder of the financial year.
January 14, 2021 01:59 ET | Source: Chr. Hansen Holding A/S
Company Announcement No. 01
Strong organic growth and good commercial traction; integration of acquisitions on track
Q1 2020/21 organic sales growth was 10%, equally split between volume/mix and price, and driven by Health & Nutrition which delivered 15% growth while Food Cultures & Enzymes delivered 8% growth
Underlying EBIT margin b.s.i. (see reconciliation on p. 20) of 28.5%, incl. 1%-point negative currency impact, compared to 29.0% in Q1 2019/20. Reported EBIT margin b.s.i. (incl. all acquisition impacts) was 25.2%
Integration of probiotic acquisitions well on track, but temporary capacity constraints in HMO will phase part of expected FY21 revenues and capex to FY22
Outlook for 2020/21 is unchanged on all key parameters
CEO Mauricio Graber says: “Our first quarter came in quite strong on a relatively easy comparable from Q1 last year, with good performance across our business, especially within Health & Nutrition. We were able to win new business, launch new products in Food Cultures & Enzymes and drive upselling in key markets such as cheese – all despite the difficulties of COVID-19. We have more product launches scheduled for the current financial year, which will help to ensure that we have a healthy commercial pipeline in the years to come.
Chr. Hansen is on track to execute on our 2025 strategy and become a focused bioscience company based on a unique microbial and fermentation technology platform. This is a year of transition, where we need to secure a succesful integration of the acquired businesses. We have started out strong, and we will address any challenges that may arise in those processes head on and with determination. The divestment process of Natural Colors is also on track and the business delivered as expected.
Our outlook for 2020/21 remains cautious, and despite COVID-19 we are able to maintain our outlook on all key parameters. This means that we will still outgrow the underlying markets as we strive to deliver industry-leading growth rates.”
Outlook for 2020/21
Organic revenue growth: 5-8%
EBIT margin before special items: 27-28%
Free cash flow before special items, acquisitions and divestments: EUR 120-160 million
The guidance for EBIT margin before special items and for free cash flow before acquisitions and special items assumes constant currencies from the time of this announcement and for the remainder of the financial year.
Antwort auf Beitrag Nr.: 65.360.973 von goetz12 am 12.10.20 17:43:02Heute kam in Galileo Sat 1 ein Bericht über diese Firma ganz toll jetzt 20 000 Bakterien sollte man beobachten
Trading Spotlight
Dass die Aktie teuer ist, kann ja auch heißen dass sie gut ist? Der letzte Rücksetzer ist vielleicht eine Möglichkeit?
Bin vor Kurzem in folgenden Video auf Christian Hanson aufmerksam geworden.
Der Hedgefondsmanager Hempton gibt eine breiten Überblick übe seine Strategie.
Als "bestes" Geschäftsmodell überhaupt bezeichnet er Hansen.
Natürlich bemängelt er auch dass die Aktie teuer ist.Bei Rückschläge will er seine Position ausbauen.
Der Hedgefondsmanager Hempton gibt eine breiten Überblick übe seine Strategie.
Als "bestes" Geschäftsmodell überhaupt bezeichnet er Hansen.
Natürlich bemängelt er auch dass die Aktie teuer ist.Bei Rückschläge will er seine Position ausbauen.
Antwort auf Beitrag Nr.: 59.247.997 von haowenshan am 19.11.18 12:39:16
Wenn der Wert 5 Jahre weitergewachsen ist, müsste er, zum Kaufkurs berechnet, fair bewertet sein.
Ob man das Wachstum so fortschreiben kann?
Was ist, wenn der Laden von Nachhaltigkeitsaposteln gemieden wird. Sei es, dass das dort erzeugte Enzym Krebs hervorruft. Und so weiter.
Watchlist ist gut, Mini Miniportion ebenfalls, <<als 1 Prozent des Depotwerts. Ich setz den mal auch auf die Watchlist.
Ich setz den mal auch auf die Watchlist!
Im Global 100 Ranking hat diese Firma den ersten Platz, 83 von 100 Punkte. Klar ist, dass Nachhaltigkeitsfonds nicht an diesem Wert vorbeikommen.Wenn der Wert 5 Jahre weitergewachsen ist, müsste er, zum Kaufkurs berechnet, fair bewertet sein.
Ob man das Wachstum so fortschreiben kann?
Was ist, wenn der Laden von Nachhaltigkeitsaposteln gemieden wird. Sei es, dass das dort erzeugte Enzym Krebs hervorruft. Und so weiter.
Watchlist ist gut, Mini Miniportion ebenfalls, <<als 1 Prozent des Depotwerts. Ich setz den mal auch auf die Watchlist.
historisch: Lab zur Käseerzeugung
Produktpalette erweitert mit diversen Kulturen (probiotisch), Enzyme, natürliche Farben, etc.
interessantes & hochprofitables Unternehmen, leider absurd hohe Bewertung
Watchlist
Produktpalette erweitert mit diversen Kulturen (probiotisch), Enzyme, natürliche Farben, etc.
interessantes & hochprofitables Unternehmen, leider absurd hohe Bewertung
Watchlist
DurchsuchenBeitrag schreiben
